This paper evaluates the reasons behind the rise in the use of proton beam for prostate cancer, the economics drivers behind it, and the evidence that exists to support it. It concludes that clinical outcome data underlying the notion that this is a superior treatment remains sparse and discusses what is needed to fill in the gaps.

National Use of Proton Pump Inhibitors From2007 to 2011 Proton pump inhibitors (PPIs) are a class of therapeutically equivalent medications when used at equivalent doses.1,2 Despite this, high-cost PPIs continue to be used when lowcost equivalents are available. We sought to estimate the national loss associated with the use of high-cost PPIs over their lower-cost alternatives. Furthermore, we ...

We have investigated the contribution of Higher Twist (HT) Feynman diagrams to large-$p_T$ inclusive $\rho_L$ meson production cross section in proton-proton and proton-antiproton collisions we discuss phenomenological consequences possible HT contributions sections. To extract subprocesses from Leading (LT) background, use various distribution amplitudes(DAs). In numerical calculations, depend...